"Jelly Shoes Are Back in Style": TOEBOX KOREA, Ltd. Reports 38% Increase in Melissa Sales in the First Half of the Year
Melissa and Mini Melissa Report First-Half Sales of Approximately 7 Billion Won
Sales Increase Through Expansion of Adult Product Lines and Pop-Up Store Operations
[E-Daily Reporter Hyera Lee ] TOEBOX KOREA, Ltd.(215480)announced on the 15th that sales of the global jelly shoe brand “Melissa” and its children’s line “Mini Melissa” increased by 38% year-over-year in the first half of this year. TOEBOX KOREA, Ltd. CI. (Photo = TOEBOX KOREA, Ltd.) Sales for Melissa and Mini Melissa in the first half of the year totaled approximately 7 billion won, up from about 5 billion won during the same period last year. TOEBOX KOREA, Ltd. explained that the sales increase was driven by jelly shoes re-emerging as a fashion trend this year—fueled by the “jelly shoe customization craze”—as well as the expansion of the adult product line and the operation of pop-up stores. TOEBOX KOREA, Ltd. stated that, starting this year, it has expanded its Melissa product line for adult women in addition to its existing lineup focused on infants and children, and that sales of both adult and children’s products have increased, driven by the “matching outfits” trend where parents and children wear similar styles. The company also boosted brand awareness by operating pop-up stores at major department stores and expects demand for jelly shoes to continue growing as the peak summer and rainy seasons begin. TOEBOX KOREA, Ltd. stated, “Both Melissa and Mini Melissa are showing steady sales growth,” adding, “We will continue to expand our product lineup and distribution channels to strengthen our presence in the domestic jelly shoe market.”
Due to weak bank performance, BNK Financial Group Inc.’s third-quarter net income fell by nearly 30% compared to last year.
BNK Financial Group headquarters. (Photo courtesy of BNK Financial Group)…
Wanted Lab Inc.(376980)is hosting an in-person job fair to directly connect developers with companies in response to growing demand for "Chonbang Engineers" (FDE).
Photo courtesy of WantedLab Inc.…
SillaJen, Inc.(215600)has confirmed initial antitumor effects in a Phase 1 clinical trial of its new anticancer drug candidate, “BAL0891,” currently under development. In an interim analysis of patien…